1998
DOI: 10.1016/s0022-1759(98)00077-5
|View full text |Cite
|
Sign up to set email alerts
|

Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
121
0
9

Year Published

2002
2002
2013
2013

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 220 publications
(131 citation statements)
references
References 109 publications
1
121
0
9
Order By: Relevance
“…In this system, the protein posttranslational modifications are similar to those found in mammalian cells (Verma et al 1998). In addition, insect cells present several advantages when compared to mammalian cells, such as ease of culture, higher tolerance to osmolality (Olejnik et al 2003) and much higher expression levels when infected with recombinant baculovirus (Ikonomou et al 2003).…”
Section: *Corresponding Authorsupporting
confidence: 55%
“…In this system, the protein posttranslational modifications are similar to those found in mammalian cells (Verma et al 1998). In addition, insect cells present several advantages when compared to mammalian cells, such as ease of culture, higher tolerance to osmolality (Olejnik et al 2003) and much higher expression levels when infected with recombinant baculovirus (Ikonomou et al 2003).…”
Section: *Corresponding Authorsupporting
confidence: 55%
“…The sequence requirements that make an scFv very stable such that it might also function in an intracellular environment are only now emerging. 2 We have recently described a model system to measure the binding activity of a series of cytoplasmically expressed scFvs in yeast (15). These scFvs, which carry the same CDR loops on different frameworks, were all directed against the dimerization domain of the sequence-specific transcriptional activator Gcn4 (16).…”
mentioning
confidence: 99%
“…These characteristics have been exploited to turn the natural antibodies into powerful biotechnological tools in diagnostic and therapeutic applications. Advances in recombinant DNA technology have facilitated the manipulation, cloning, and expression of the antibody genes in a wide variety of hosts (1)(2)(3). Several forms of antibodies have been constructed to obtain derivatives that carry the binding site in a smaller assembly.…”
mentioning
confidence: 99%
“…The expression of several antibody fragments was evaluated in the BEVS and in stable transfected S2 cells. Reported maximum concentrations of the recombinant antibody fragments were 9 mg/L in the BEVS and 0.4 mg/L in S2 cells [23]. Production of recombinant human IL-7 in the BEVS and stable transfected Sf cells revealed in 10 times higher expression levels for the BEVS [24].…”
Section: Expression Of Two Different Proteins (Extracellular Vascularmentioning
confidence: 95%